Low-power versus high-power laser for holmium laser enucleation of prostate: systematic review and meta-analysis
Abstract
Holmium laser enucleation of the prostate (HoLEP) has emerged as a minimally invasive alternative to transurethral resection of the prostate (TURP), offering benefits such as reduced bleeding and faster recovery. While high-power (HP, 80–100 W) is widely used, low-power (LP, 20–50 W) has gained attention for its cost-effectiveness and versatility. This study presents the first meta-analysis of randomized controlled trials (RCTs) comparing the outcomes of low-power (LP) and high-power (HP) HoLEPin patients with benign prostatic hyperplasia (BPH). RCTs were retrieved from PubMed, Embase, Web of Science, and the Cochrane Library up to February 28, 2025. Primary outcomes included the International Prostate Symptom Score (IPSS) at three months and intraoperative enucleation efficiency (EE). Secondary outcomes encompassed IPSS, maximum urinary flow rate (Qmax), post-void residual urine volume (PVR), quality of life (QoL) at three and six months, as well as complication incidence and hemoglobin decrease. Statistical analysis was performed using RevMan 5.3. Five studies involving 488 patients (242 in the LP group and 246 in the HP group) were included, with low heterogeneity. LP- and HP-HoLEP demonstrated comparable outcomes in IPSS (MD: 0.45 points, p = 0.35), Qmax (MD: 0.30 mL/s, p = 0.49), PVR (MD: -2.92 mL, p = 0.53), and QoL (MD: 0.16 points, p = 0.46) at three months, with similar results observed at six months. LP-HoLEP showed lower EE (MD: -0.17 g/min, p < 0.00001) but no…
How strong is the evidence?
Evidence Hub reads this as a meta-analysis, done in people. Its evidence level is 1 of 5 (Highest · pooled evidence). Pooled evidence from several studies sits at the top of the evidence pyramid. Reported size: 488 participants or records.
Read the paper
Related studies
- Treatment of non-metastatic castration-resistant prostate cancer: facing age-related comorbidities and drug–drug interactions
- The Efficacy of Flogofilm® in the Treatment of Chronic Bacterial Prostatitis as an Adjuvant to Antibiotic Therapy: A Randomized Prospective Trial
- Inhibition of growth and contraction in human prostate stromal cells by silencing of NUAK1 and -2, and by the presumed NUAK inhibitors HTH01-015 and WZ4003
- Effectiveness and Safety of a New Nutrient Fixed Combination Containing Pollen Extract Plus Teupolioside, in the Management of LUTS in Patients with Benign Prostatic Hypertrophy: A Pilot Study
- Extract from Cucurbita pepo improves BPH symptoms without affecting sexual function: a 24-month noninterventional study
- Aquablation vs. holmium laser enucleation of the prostate for benign prostatic hyperplasia: a 150-patients prospective comparative multicenter study
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.